Table 1 General characteristics of patients.
PEG-rhG-CSF (n = 33) | rhG-CSF (n = 37) | p value | |
|---|---|---|---|
Median age, years (range) | 55.8 (41–69) | 54.8 (36–70) | 0.587 |
Sex, n (%) | 0.224 | ||
Male | 17 (51.5%) | 25 (67.6%) | |
Female | 16 (48.5%) | 12 (32.4%) | |
Induction therapy protocols | BRD | BRD | – |
DS staging, n (%) | 0.357 | ||
I | 0 | 0 | |
II | 3 (9.1%) | 2 (5.4%) | |
III | 30 (90.9%) | 35 (95.6%) | |
ISS staging, n (%) | 0.637 | ||
I | 11 (33.3%) | 11 (29.7%) | |
II | 9 (27.3%) | 14 (37.8%) | |
III | 13 (39.4%) | 12 (32.4%) | |
R-ISS staging, n (%) | 0.424 | ||
I | 8 (24.2%) | 11 (29.7%) | |
II | 15 (45.5%) | 17 (45.9%) | |
III | 10 (30.3%) | 9 (24.3%) | |
Classification of active MM (mSMART 3.0), n (%) | 0.091 | ||
High-risk | 17 (51.5%) | 21 (56.8%) | |
Standard-risk | 16 (48.5%) | 16 (43.2%) | |
Disease status at ASCT, n (%) | 1.299 | ||
CR | 23 (69.7%) | 23 (62.2%) | |
VGPR | 8 (24.2%) | 13 (35.1%) | |
PR | 2 (6.1%) | 1 (2.7%) | |
